Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05392881 · ClinicalTrials.gov registry record
Interstitial Lung Disease Research Unit Biobank
A clinical trial of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05392881: Recruiting study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by University of Kansas Medical Center.
NCT05392881 is a study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 1,000 participants, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05392881, a study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Conditions Studied
Study Locations (1)
Kansas
- The University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2032-03-01 |
What NCT05392881 shows while recruiting
NCT05392881 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher).
The record links to 5 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT05392881 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05392881 about?
NCT05392881 is a clinical study titled "Interstitial Lung Disease Research Unit Biobank". Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
What is the current status of trial NCT05392881?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-08-09. Estimated completion is 2032-03-01.
What conditions does trial NCT05392881 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Fibrosis, Sarcoidosis, Hypersensitivity Pneumonitis.
Who is sponsoring clinical trial NCT05392881?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05392881 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05392881's enrollment target sits among peer trials
1,000 7th of 51 higher than 44 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI